BACKGROUND: Portugal is currently facing a serious economic and financial crisis, which is dictating some important changes in the health care sector. Some of these measures may potentially influence patients' access to medication and consequently adherence, which will ultimately impact on health status, especially in chronic patients. AIMS: This study aimed at providing a snapshot of adherence in patients with chronic conditions in Portugal between March and April 2012. SETTING: Community pharmacy in Portugal. METHOD: A cross-sectional pilot study was undertaken, where patients were recruited via community pharmacies to a questionnaire study evaluating the number of prescribed and purchased drugs and, when these figures were inconsistent, the reasons for this. MAIN OUTCOME MEASURES: Primary and secondary adherence measures. Failing to purchase prescription items was categorized as primary nonadherence. Secondary nonadherence was attributed to purchasing prescription items, but not taking medicines as prescribed. RESULTS: Data were collected from 375 patients. Primary nonadherence was identified in 22.8 % of patients. Regardless of the underlying condition, the most commonly reported reason for primary non-adherence was having spare medicines at home ("leftovers"), followed by financial problems. The latter appeared to be related to the class of medicines prescribed. Primary non-adherence was associated with low income (<475 <euro>/month; p = 0.026). Secondary non-adherence, assessed by the 7-MMAS was detected in over 50 % of all patients, where unintentional nonadherence was higher than intentional nonadherence across all disease conditions. CONCLUSION: This study revealed that more than one fifth of chronic medication users report primary nonadherence (22.8 %) and more than 50 % report secondary nonadherence. Data indicates that the existence of spare medicines and financial constraints occurred were the two most frequent reasons cited for nonadherence (47, 6-64, 8 and 19-45.5 %, depending on the major underlying condition, respectively).
BACKGROUND: Portugal is currently facing a serious economic and financial crisis, which is dictating some important changes in the health care sector. Some of these measures may potentially influence patients' access to medication and consequently adherence, which will ultimately impact on health status, especially in chronic patients. AIMS: This study aimed at providing a snapshot of adherence in patients with chronic conditions in Portugal between March and April 2012. SETTING: Community pharmacy in Portugal. METHOD: A cross-sectional pilot study was undertaken, where patients were recruited via community pharmacies to a questionnaire study evaluating the number of prescribed and purchased drugs and, when these figures were inconsistent, the reasons for this. MAIN OUTCOME MEASURES: Primary and secondary adherence measures. Failing to purchase prescription items was categorized as primary nonadherence. Secondary nonadherence was attributed to purchasing prescription items, but not taking medicines as prescribed. RESULTS: Data were collected from 375 patients. Primary nonadherence was identified in 22.8 % of patients. Regardless of the underlying condition, the most commonly reported reason for primary non-adherence was having spare medicines at home ("leftovers"), followed by financial problems. The latter appeared to be related to the class of medicines prescribed. Primary non-adherence was associated with low income (<475 <euro>/month; p = 0.026). Secondary non-adherence, assessed by the 7-MMAS was detected in over 50 % of all patients, where unintentional nonadherence was higher than intentional nonadherence across all disease conditions. CONCLUSION: This study revealed that more than one fifth of chronic medication users report primary nonadherence (22.8 %) and more than 50 % report secondary nonadherence. Data indicates that the existence of spare medicines and financial constraints occurred were the two most frequent reasons cited for nonadherence (47, 6-64, 8 and 19-45.5 %, depending on the major underlying condition, respectively).
Authors: Carmel M Hughes; Ahmed F Hawwa; Claire Scullin; Claire Anderson; Cecilia B Bernsten; Ingunn Björnsdóttir; Maria A Cordina; Filipa Alves da Costa; Isabelle De Wulf; Patrick Eichenberger; Veerle Foulon; Martin C Henman; Kurt E Hersberger; Marion A Schaefer; Birthe Søndergaard; Mary P Tully; Tommy Westerlund; James C McElnay Journal: Pharm World Sci Date: 2010-05-11
Authors: Rob Horne; Sarah C E Chapman; Rhian Parham; Nick Freemantle; Alastair Forbes; Vanessa Cooper Journal: PLoS One Date: 2013-12-02 Impact factor: 3.240
Authors: Zoltan Kiss; Laszlo Nagy; Istvan Reiber; György Paragh; Mark Peter Molnar; György Rokszin; Zsolt Abonyi-Toth; Laszlo Mark Journal: Arch Med Sci Date: 2013-05-27 Impact factor: 3.318
Authors: Ignacio Aznar-Lou; Ana Fernández; Montserrat Gil-Girbau; Marta Fajó-Pascual; Patricia Moreno-Peral; María Teresa Peñarrubia-María; Antoni Serrano-Blanco; Albert Sánchez-Niubó; María Antonia March-Pujol; Anna Maria Jové; Maria Rubio-Valera Journal: Br J Clin Pharmacol Date: 2017-02-24 Impact factor: 4.335
Authors: Filipa Alves da Costa; Inês Teixeira; Filipa Duarte-Ramos; Luís Proença; Ana Rita Pedro; Cristina Furtado; José Aranda da Silva; José Cabrita Journal: Int J Clin Pharm Date: 2016-12-09
Authors: Carla Torre; José Guerreiro; Patrícia Longo; João Filipe Raposo; Hubert Leufkens; Ana Paula Martins Journal: Patient Prefer Adherence Date: 2018-08-17 Impact factor: 2.711